Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD(TM) CorEvitas(TM) Myasthenia Gravis (MG) Registry. This ...
Takenobu Y, Kikuchi T, Ishikawa D, et al. Rozanolixizumab as rescue therapy in triple seronegative refractory generalized ...
Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a ...
When patients present with progressive keratoconus in both eyes, it is important to ensure that they don’t become lost to follow-up before both eyes can be treated with corneal cross-linking. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback